Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03259087 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT03259087 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 42 participants.
The verdict
NCT03259087, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
The purpose of this study is to compare plasma and urine PK parameters of MK-3866 between participants with impaired renal function and healthy control participants, to investigate the extent to which MK-3866 is removed from the plasma by hemodialysis (HD), and evaluate the safety and tolerability of MK-3866 in participants with impaired renal function.
Interventions
- DRUG MK-3866
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2017-09-01 |
| Est. Completion | 2018-02-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03259087
The ClinicalTrials.gov registry entry for NCT03259087 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MK-3866 is the first listed.
NCT03259087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03259087 about?
NCT03259087 is a clinical study titled "Pharmacokinetics (PK) and Safety of a Single Intravenous (IV) Dose of MK-3866 in Participants With Impaired Renal Function and in Healthy Controls (MK-3866-005)". The purpose of this study is to compare plasma and urine PK parameters of MK-3866 between participants with impaired renal function and healthy control participants, to investigate the extent to which MK-3866 is removed from the plasma by hemodialysis (HD), and evaluate the safety and tolerability o...
What is the current status of trial NCT03259087?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2017-09-01. Estimated completion is 2018-02-09.
What interventions are being tested in trial NCT03259087?
The interventions under investigation include: MK-3866 (DRUG).
Who is sponsoring clinical trial NCT03259087?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.